Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Jun;41(6):886–891. doi: 10.1038/bjc.1980.165

Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro.

H Eichholtz-Wirth
PMCID: PMC2010346  PMID: 7426313

Abstract

The surviving fraction (SF) of Chinese hamster cells and HeLa cells after treatment with a range of Adriamycin concentrations and exposure times was determined. The cytostatic effect was proportional to the product of extracellular drug concentration (c) and exposure time (t) according to the equation: SF=e-ktc. By determining the intracellular drug concentration at various exposures, it could be shown that absorbed dose is not proportional to exposure dose.

Full text

PDF
886

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barranco S. C., Gerner E. W., Burk K. H., Humphrey R. M. Survival and cell kinetics effects of adriamycin on mammalian cells. Cancer Res. 1973 Jan;33(1):11–16. [PubMed] [Google Scholar]
  2. Benjamin R. S., Wiernik P. H., Bachur N. R. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974 Jan;33(1):19–27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  3. Carter S. K. Adriamycin-a review. J Natl Cancer Inst. 1975 Dec;55(6):1265–1274. doi: 10.1093/jnci/55.6.1265. [DOI] [PubMed] [Google Scholar]
  4. Creasey W. A., McIntosh L. S., Brescia T., Odujinrin O., Aspnes G. T., Murray E., Marsh J. C. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res. 1976 Jan;36(1):216–221. [PubMed] [Google Scholar]
  5. Drewinko B., Gottlieb J. A. Survival kinetics of cultured human lymphoma cells exposed to adriamycin. Cancer Res. 1973 Jun;33(6):1141–1145. [PubMed] [Google Scholar]
  6. Eichholtz H., Trott K. R. Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro. Br J Cancer. 1980 Feb;41(2):277–284. doi: 10.1038/bjc.1980.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Pacciarini M. A., Barbieri B., Colombo T., Broggini M., Garattini S., Donelli M. G. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep. 1978 May;62(5):791–800. [PubMed] [Google Scholar]
  8. Schwartz H. S. A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem Med. 1973 Jun;7(3):396–404. doi: 10.1016/0006-2944(73)90060-4. [DOI] [PubMed] [Google Scholar]
  9. Skipper H. E., Schabel F. M., Jr, Mellett L. B., Montgomery J. A., Wilkoff L. J., Lloyd H. H., Brockman R. W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970 Dec;54(6):431–450. [PubMed] [Google Scholar]
  10. Twentyman P. R. Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems. Cancer Treat Rep. 1976 Dec;60(12):1719–1722. [PubMed] [Google Scholar]
  11. Wheeler K. T., Levin V. A., Deen D. F. The concept of drug dose for in vitro studies with chemotherapeutic agents. Radiat Res. 1978 Dec;76(3):441–458. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES